SEC Filing Summary: Amedica Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amedica Corporation on January 22, 2016, reporting events as of January 18, 2016. The filing addresses a material modification to the rights of security holders regarding the company's common stock.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than financial performance.
Material Changes
- Reverse Stock Split: The Board of Directors has finalized a 1-for-15 reverse stock split ratio, selected from a range of 1-for-2 to 1-for-15 previously approved by stockholders.
- Effective Date: The split becomes effective at 12:01 a.m. Eastern Time on January 25, 2016.
- Trading Adjustments: Common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis on January 25, 2016.
- CUSIP Change: The CUSIP number for the common stock will change to 023435 209.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors beyond the procedural details of the stock split. The document references a Certificate of Amendment filed with the Delaware Secretary of State for full legal details.
Key Facts for Investor Verification
- Verify the 1-for-15 reverse split ratio and its effective time of January 25, 2016.
- Confirm the new CUSIP number (023435 209) for trading purposes.
- Review the attached Certificate of Amendment (Exhibit 3.1) for specific terms regarding fractional shares and record dates.
- Note that the registrant name in the filing is Amedica Corporation, despite the request metadata referencing Sintx Technologies, Inc.